[Skip to Content]
[Skip to Content Landing]
Views 253
Citations 0
Brief Report
September 5, 2019

Clinical Characterization of Retinitis Pigmentosa Associated With Variants in SNRNP200

Author Affiliations
  • 1Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, Oxford University, John Radcliffe Hospital, Oxford, United Kingdom
  • 2Oxford Eye Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS (National Health Service) Foundation Trust, Oxford, United Kingdom
  • 3Department of Ophthalmology, University of Bonn, Bonn, Germany
  • 4Oxford Medical Genetics Laboratories, Oxford University Hospitals NHS Foundation Trust, The Churchill Hospital, Oxford, United Kingdom
JAMA Ophthalmol. Published online September 5, 2019. doi:10.1001/jamaophthalmol.2019.3298
Key Points

Question  What are the clinical features and retinal imaging characteristics of patients with retinitis pigmentosa secondary to variants in SNRNP200?

Findings  This study of 9 patients found that SNRNP200-related retinitis pigmentosa is frequently characterized by nyctalopia in the first 2 decades of life with slow disease progression. Retinal appearance, fundus autofluorescence, and optical coherence tomography imaging findings and electroretinography studies were typical of a rod-predominant dystrophy.

Meaning  These data suggest that patients with variants in SNRNP200 demonstrate a clinical presentation of nonsyndromic retinitis pigmentosa with phenotypic heterogeneity and nonpenetrance.

Abstract

Importance  SNRNP200 is a recently identified genetic cause of autosomal dominant retinitis pigmentosa (RP). However, the associated retinal phenotype is not well characterized.

Objective  To describe the retinal phenotype in patients with RP secondary to variants in SNRNP200.

Design, Setting, and Participants  This retrospective, case-series study was performed at 2 tertiary referral centers for inherited retinal diseases. Participants included 9 consecutive patients from 8 families with RP attributed to variants in SNRNP200. Data were collected from August 2017 to March 2018 and analyzed from May to July 2018.

Main Outcomes and Measures  Results of clinical evaluation, multimodal retinal imaging, and molecular genetic testing using targeted next-generation sequencing.

Results  Of the 9 patients included in the analysis (4 female and 5 male; mean [SD] age at presentation, 19 [15] years), each presented with nyctalopia, typically in the first 2 decades of life, although 2 patients experienced symptom onset in middle age. None had any consistent systemic features suggestive of syndromic RP. Retinal imaging studies and electroretinography findings were typical of a rod-predominant dystrophy with later involvement of cone photoreceptors. Phenotypic heterogeneity was typified by 4 unrelated patients with the common c.2041C>T SNRNP200 variant who demonstrated a variable age of disease onset (middle teenage years to the fourth decade of life). Disease progression was slow, with all but 1 patient maintaining visual acuity of better than 20/40 in the better-seeing eye in the fifth and sixth decades of life.

Conclusions and Relevance  These data suggest that variants in SNRNP200 result in nonsyndromic RP with a typical phenotype of a rod-predominant dystrophy. Significant phenotypic heterogeneity and nonpenetrance were noted within some affected families. Symptom onset was typically within the first 2 decades of life, with slow progression and well-preserved visual acuities into the fifth and sixth decades.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×